Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2024 | Exploring checkpoint inhibition in high-grade ER+ breast cancer

Sara Tolaney • 17 Sep 2024
ESMO 2024
Breast Cancer Antibodies Checkpoint Inhibitors
CheckMate 7FL KEYNOTE-756

Sara Tolaney, MD, MPH, Dana Farber Cancer Institute, Boston, MA, gives an overview of findings from trials examining checkpoint inhibitors in high-grade ER+ breast cancer, particularly data from KEYNOTE-756 (NCT03725059) and CheckMate 7FL (NCT04109066). These trials assessed adding a checkpoint inhibitor to chemotherapy in the preoperative setting, showing improved pathologic complete response (PCR) rates. Future data on event-free survival (EFS) and biomarker analysis, especially for PD-L1, are needed to guide patient selection and confirm long-term benefits. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Sara Tolaney

Optimizing ADCs in mBC: boosting efficacy & managing toxicity in earlier treatment lines
1:11
Optimizing ADCs in mBC: boosting efficacy & managing toxicity in earlier treatment lines
Sara Tolaney • 20 Oct 2025
ADCs in earlier-line metastatic breast cancer: insights from DESTINY-Breast09 & ASCENT-03
2:02
ADCs in earlier-line metastatic breast cancer: insights from DESTINY-Breast09 & ASCENT-03
Sara Tolaney • 20 Oct 2025
Remaining questions surrounding the use of T-DXd in the curative-intent setting
2:02
Remaining questions surrounding the use of T-DXd in the curative-intent setting
Sara Tolaney • 20 Oct 2025
T-DXd vs T-DM1 in high-risk HER2+ breast cancer: DESTINY-Breast05 interim data
1:51
T-DXd vs T-DM1 in high-risk HER2+ breast cancer: DESTINY-Breast05 interim data
Sara Tolaney • 20 Oct 2025

Related Videos

Omitting adjuvant radiotherapy in older patients with early-stage breast cancer
2:12
Omitting adjuvant radiotherapy in older patients with early-stage breast cancer
Lotte Bouwman • 24 Oct 2026
When can endocrine therapy be omitted in early breast cancer?
3:26
When can endocrine therapy be omitted in early breast cancer?
Lotte Bouwman • 24 Oct 2026
How will SARMs fit into the current breast cancer treatment paradigm?
1:14
How will SARMs fit into the current breast cancer treatment paradigm?
Rafael Grochot • 2 Jul 2026
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
1:35
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
Rafael Grochot • 2 Jul 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals